Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Biotech
ASCO: Regeneron's Opdualag rival records 61% response rate
At ASCO, Regeneron will make the case for its LAG-3 inhibitor combo in advanced melanoma as a rival to Bristol Myer Squibb’s Opdualag.
Gabrielle Masson
May 25, 2023 6:00pm
BMS' pulmonary fibrosis drug reduces lung function decline
May 22, 2023 1:05pm
Merck battled 2 other Big Pharmas in pursuit of Prometheus
May 2, 2023 10:55am
BMS CEO set to leave after 8-year run—Chutes & Ladders
Apr 28, 2023 9:30am
Bristol Myers pays Tubulis $23M to develop solid tumor ADCs
Apr 20, 2023 5:00am
Evotec shuts down network after cyberattack
Apr 10, 2023 10:24am
